# Checkpoint Blockade in COVID-19 Pandemic

> **NCT04335305** · PHASE2 · TERMINATED · sponsor: **MedSIR** · enrollment: 12 (actual)

## Conditions studied

- COVID-19
- Pneumonia, Viral

## Interventions

- **DRUG:** Tocilizumab
- **BIOLOGICAL:** Pembrolizumab (MK-3475)

## Key facts

- **NCT ID:** NCT04335305
- **Lead sponsor:** MedSIR
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-04-09
- **Primary completion:** 2021-03-08
- **Final completion:** 2021-06-21
- **Target enrollment:** 12 (ACTUAL)
- **Why stopped:** Recruitment issues
- **Last updated:** 2022-06-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04335305

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04335305, "Checkpoint Blockade in COVID-19 Pandemic". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT04335305. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*